Thus, we demonstrate that stroke-associated comorbidity accompanying NOS3 dysfunctions may depreciate the early phase benefits of RIC in thrombotic stroke, which needs to be carefully investigated in clinical trials. The gene discussed is NOS3; the disease is Stroke.